Figure 5: CP2 derivatives stabilize KDM4A and alter histone methylation status in cells.
From: Highly selective inhibition of histone demethylases by de novo macrocyclic peptides

(a) Sequences of peptides with modifications on CP2 (CP2.1, CP2.2 and CP2.3) used for cellular assays. (b,c) KDM4A stability is enhanced for CP2-treated cells in CETSA. (b) CETSA melting curves for Flag-KDM4A in U2OS cells with and without CP2(T13Z) treatment (0.5 μM). The actin Tm was 55 °C for treated and untreated cells. (c) Isothermal dose–response titration CETSAs of dosed U2OS cells at 55 °C demonstrate that both CP2 and CP2.3 stabilize KDM4A in a dose-dependent manner. Average±s.e.m. are shown (n>3, biological). Representative western blotting figures are shown.